バイオエンジニアリングタンパク質医薬品市場：薬剤タイプ、疾患、エンドユーザー別-2025～2030年世界予測

バイオエンジニアリングタンパク質医薬品市場は、2023年に3,870億3,000万米ドルと評価され、2024年には4,151億3,000万米ドルに達すると予測され、CAGR 7.76％で成長し、2030年には6,533億5,000万米ドルに達すると予測されています。

バイオエンジニアリングタンパク質医薬品は生物製剤としても知られ、組み換えDNA技術によって作られた治療用タンパク質を指し、がん、糖尿病、自己免疫疾患など様々な疾患の治療に不可欠です。その必要性は、高精度で特定の経路を標的とする能力に起因しており、従来の低分子医薬品では不十分な治療の選択肢を記載しています。モノクローナル抗体、ワクチン、ホルモン治療などの用途があり、最終用途は病院、クリニック、研究機関など多岐にわたります。同市場は、慢性疾患の蔓延、遺伝子工学やタンパク質工学の技術進歩、政府による支援的規制など、いくつかの要因によって影響を受けています。高齢者の増加と医療提供者の生物製剤に対する意識の高まりが、需要をさらに押し上げています。潜在的なビジネス機会としては、先端治療へのアクセスが限られている新興市場への進出や、個別化医療アプローチを含む製品ポートフォリオの多様化が挙げられます。バイオテクノロジー企業間の戦略的提携は研究開発能力を強化し、画期的なイノベーションと迅速な商業化を可能にします。しかし、高い開発コスト、複雑な製造プロセス、厳しい規制要件、バイオシミラーとの競合といった課題が制約となっています。さらに、市場成長は価格圧力や特許切れによって制約を受ける。事業成長のためには、ドラッグデリバリーシステムとバイオプロセス技術の革新に注力し、製品の有効性と患者のコンプライアンスを向上させることが重要です。費用対効果と信頼性を備えたバイオシミラーの開拓は、特許切れ後の市場シェアを獲得することができます。さらに、薬剤開発と患者選択において人工知能と機械学習を探求することで、治療応用を洗練させることができます。市場は急速な技術進化と研究開発への多額の投資を特徴としており、継続的なイノベーションの必要性が強調されています。企業は、競争優位性を維持し、新たな市場動向を捉えるために、データ主導の意思決定を採用し、戦略的提携に積極的に取り組むことで、バイオエンジニアリングタンパク質医薬品セグメントの持続的成長を確保すべきです。

市場力学：急速に進化するバイオエンジニアリングタンパク質医薬品市場の主要市場洞察を公開

バイオエンジニアリングタンパク質医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 人口の慢性疾患有病率の上昇
  • 医療に対する意識の高まりとバイオエンジニアリングタンパク質医薬品の大きなメリット
  • 各国における医療支出の増加
• 市場抑制要因
  • バイオエンジニアリングタンパク質医薬品に関連する高コスト
• 市場機会
  • 新規バイオエンジニアリングタンパク質医薬品の開発・導入に向けた研究活動の活発化
  • 高分子送達におけるナノ技術の新たな用途
• 市場課題
  • 厳しく時間のかかる承認プロセス

ポーターの5つの力：バイオエンジニアリングタンパク質医薬品市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：バイオエンジニアリングタンパク質医薬品市場における外部からの影響の把握

外部マクロ環境要因は、バイオエンジニアリングタンパク質医薬品市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：バイオエンジニアリングタンパク質医薬品市場における競合情勢の把握

バイオエンジニアリングタンパク質医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックスバイオエンジニアリングタンパク質医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、バイオエンジニアリングタンパク質医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：バイオエンジニアリングタンパク質医薬品市場における成功への道筋を描く

バイオエンジニアリングタンパク質医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における慢性疾患の罹患率の上昇
    • 医療意識の高まりとバイオエンジニアリングタンパク質医薬品の大きなメリット
    • 各国の医療費支出増加
  • 抑制要因
    • バイオエンジニアリングタンパク質医薬品に関連する高コスト
  • 機会
    • 新たなバイオエンジニアリングタンパク質医薬品の開発と導入に向けた調査活動の拡大
    • 高分子送達におけるナノ技術の新たな用途
  • 課題
    • 厳格で時間のかかる承認プロセス
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 バイオエンジニアリングタンパク質医薬品市場：薬剤タイプ別

• イントロダクション
• モノクローナル抗体
• 治療用タンパク質
• ワクチン

第7章 バイオエンジニアリングタンパク質医薬品市場：疾患別

• イントロダクション
• 関節炎
• 自己免疫疾患
• 血液疾患
• がん
• 先天性疾患
• 心臓病
• 感染症
• 神経変性疾患
• 呼吸器疾患
• 皮膚疾患

第8章 バイオエンジニアリングタンパク質医薬品市場：エンドユーザー別

• イントロダクション
• CRO
• 製薬・バイオテクノロジー企業
• 研究機関

第9章 南北アメリカのバイオエンジニアリングタンパク質医薬品市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のバイオエンジニアリングタンパク質医薬品市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのバイオエンジニアリングタンパク質医薬品市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Ambrx, Inc.
• AMGEN INC.
• Aravive, Inc.
• Astrazeneca PLC
• Baxter Healthcare
• Bayer Pharmaceuticals
• BRISTOL-MYERS SQUIBB
• CSL LTD.
• F. HOFFMANN-LA ROCHE AG
• GLAXOSMITHKLINE PLC
• GRIFOLS S.A.
• Hoffman-la-Roche
• MERCK & CO., INC.
• NOVARTIS AG
• NOVO NORDISK A/S
• PFIZER INC.
• Polaris Group
• REGENERON PHARMACEUTICALS INC.
• SANOFI
• TAKEDA PHARMACEUTICAL CO., LTD.

LIST OF FIGURES

• FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOENGINEERED PROTEIN DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CONGENITAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 55. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 58. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 110. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 122. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 125. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 154. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Bioengineered Protein Drugs Market was valued at USD 387.03 billion in 2023, expected to reach USD 415.13 billion in 2024, and is projected to grow at a CAGR of 7.76%, to USD 653.35 billion by 2030.

Bioengineered protein drugs, also known as biologics, refer to therapeutic proteins created through recombinant DNA technology and are essential for treating various diseases such as cancer, diabetes, and autoimmune disorders. Their necessity stems from their ability to target specific pathways with high precision, offering treatment options where traditional small-molecule drugs fall short. Applications include monoclonal antibodies, vaccines, and hormone treatments, with end-use spanning hospitals, clinics, and research institutions. The market is influenced by several factors, such as increasing prevalence of chronic diseases, technological advancements in genetic and protein engineering, and supportive government regulations. A growing geriatric population and heightened awareness of biologics among healthcare providers further drive demand. Potential opportunities include expanding into emerging markets with limited access to advanced therapeutics and diversifying product portfolios to include personalized medicine approaches. Strategic alliances between biotech firms can enhance R&D capabilities, enabling breakthrough innovations and faster commercialization. However, challenges such as high development costs, complex manufacturing processes, stringent regulatory requirements, and competition from biosimilars pose limitations. Additionally, market growth is constrained by pricing pressures and patent expirations. For business growth, focusing on innovations in drug delivery systems and bioprocessing technologies to improve product efficacy and patient compliance is crucial. Developing biosimilars with cost-effectiveness and reliability can capture market share post-patent expiration. Furthermore, exploring artificial intelligence and machine learning in drug development and patient selection can refine therapeutic applications. The market is characterized by rapid technological evolution and significant investment in research and development, underscoring the need for continuous innovation. Companies should employ data-driven decision-making and actively engage in strategic collaborations to maintain competitive advantage and capture emerging market trends, thereby ensuring sustained growth in the bioengineered protein drugs sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioengineered Protein Drugs Market

The Bioengineered Protein Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of chronic diseases among population
  • Growing healthcare awareness and significant benefits of bioengineered protein drugs
  • Increase in healthcare spending across economies
• Market Restraints
  • High costs associated with the bioengineered protein drugs
• Market Opportunities
  • Growing research activities to develop and introduce novel bioengineered protein drugs
  • Emerging applications of nanotechnology in macromolecules delivery
• Market Challenges
  • Stringent and time consuming approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Bioengineered Protein Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioengineered Protein Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioengineered Protein Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioengineered Protein Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioengineered Protein Drugs Market

A detailed market share analysis in the Bioengineered Protein Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioengineered Protein Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioengineered Protein Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioengineered Protein Drugs Market

A strategic analysis of the Bioengineered Protein Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioengineered Protein Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambrx, Inc., AMGEN INC., Aravive, Inc., Astrazeneca PLC, Baxter Healthcare, Bayer Pharmaceuticals, BRISTOL-MYERS SQUIBB, CSL LTD., F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, GRIFOLS S.A., Hoffman-la-Roche, MERCK & CO., INC., NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., Polaris Group, REGENERON PHARMACEUTICALS INC., SANOFI, and TAKEDA PHARMACEUTICAL CO., LTD..

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Monoclonal Antibodies, Therapeutic Proteins, and Vaccines.
• Based on Disease, market is studied across Arthritis, Autoimmune Disorders, Blood Disorders, Cancer, Congenital Diseases, Heart Diseases, Infectious Diseases, Neurodegenerative Diseases, Respiratory Diseases, and Skin Diseases.
• Based on End-User, market is studied across CROs, Pharmaceutical and Biotechnology Companies, and Research institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of chronic diseases among population
    • 5.1.1.2. Growing healthcare awareness and significant benefits of bioengineered protein drugs
    • 5.1.1.3. Increase in healthcare spending across economies
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the bioengineered protein drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing research activities to develop and introduce novel bioengineered protein drugs
    • 5.1.3.2. Emerging applications of nanotechnology in macromolecules delivery
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent and time consuming approval processes
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bioengineered Protein Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Monoclonal Antibodies
• 6.3. Therapeutic Proteins
• 6.4. Vaccines

7. Bioengineered Protein Drugs Market, by Disease

• 7.1. Introduction
• 7.2. Arthritis
• 7.3. Autoimmune Disorders
• 7.4. Blood Disorders
• 7.5. Cancer
• 7.6. Congenital Diseases
• 7.7. Heart Diseases
• 7.8. Infectious Diseases
• 7.9. Neurodegenerative Diseases
• 7.10. Respiratory Diseases
• 7.11. Skin Diseases

8. Bioengineered Protein Drugs Market, by End-User

• 8.1. Introduction
• 8.2. CROs
• 8.3. Pharmaceutical and Biotechnology Companies
• 8.4. Research institutes

9. Americas Bioengineered Protein Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Bioengineered Protein Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Bioengineered Protein Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Ambrx, Inc.
• 3. AMGEN INC.
• 4. Aravive, Inc.
• 5. Astrazeneca PLC
• 6. Baxter Healthcare
• 7. Bayer Pharmaceuticals
• 8. BRISTOL-MYERS SQUIBB
• 9. CSL LTD.
• 10. F. HOFFMANN-LA ROCHE AG
• 11. GLAXOSMITHKLINE PLC
• 12. GRIFOLS S.A.
• 13. Hoffman-la-Roche
• 14. MERCK & CO., INC.
• 15. NOVARTIS AG
• 16. NOVO NORDISK A/S
• 17. PFIZER INC.
• 18. Polaris Group
• 19. REGENERON PHARMACEUTICALS INC.
• 20. SANOFI
• 21. TAKEDA PHARMACEUTICAL CO., LTD.